SI3354273T1 - Melanokortinski receptor ligandi - Google Patents
Melanokortinski receptor ligandiInfo
- Publication number
- SI3354273T1 SI3354273T1 SI200632406T SI200632406T SI3354273T1 SI 3354273 T1 SI3354273 T1 SI 3354273T1 SI 200632406 T SI200632406 T SI 200632406T SI 200632406 T SI200632406 T SI 200632406T SI 3354273 T1 SI3354273 T1 SI 3354273T1
- Authority
- SI
- Slovenia
- Prior art keywords
- receptor ligands
- melanocortin receptor
- melanocortin
- ligands
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69777905P | 2005-07-08 | 2005-07-08 | |
| US74885005P | 2005-12-09 | 2005-12-09 | |
| EP17202836.7A EP3354273B1 (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3354273T1 true SI3354273T1 (sl) | 2021-10-29 |
Family
ID=37637790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200632406T SI3354273T1 (sl) | 2005-07-08 | 2006-07-10 | Melanokortinski receptor ligandi |
Country Status (21)
| Country | Link |
|---|---|
| US (9) | US8039435B2 (enExample) |
| EP (6) | EP2548568B1 (enExample) |
| JP (4) | JP4734411B2 (enExample) |
| KR (2) | KR101232201B1 (enExample) |
| CN (5) | CN119119190A (enExample) |
| AU (2) | AU2006269261B2 (enExample) |
| BE (1) | BE2021C557I2 (enExample) |
| CA (4) | CA2793119C (enExample) |
| DK (4) | DK3354273T3 (enExample) |
| ES (4) | ES2663916T3 (enExample) |
| FR (1) | FR21C1060I2 (enExample) |
| HU (4) | HUE031731T2 (enExample) |
| IL (3) | IL188545A (enExample) |
| NL (1) | NL301150I2 (enExample) |
| NZ (2) | NZ565217A (enExample) |
| PL (4) | PL3354273T3 (enExample) |
| PT (4) | PT2286825T (enExample) |
| RU (2) | RU2439079C2 (enExample) |
| SG (1) | SG163585A1 (enExample) |
| SI (1) | SI3354273T1 (enExample) |
| WO (1) | WO2007008704A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2663916T3 (es) * | 2005-07-08 | 2018-04-17 | Ipsen Pharma | Ligandos de los receptores de la melanocortina |
| DE102007020152A1 (de) * | 2007-04-26 | 2008-10-30 | Charité - Universitätsmedizin Berlin | Mittel zur antiinfektiven Behandlung eines Patienten |
| CA2689016C (en) | 2007-05-25 | 2014-08-12 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| EP2167112A4 (en) * | 2007-06-15 | 2012-01-25 | Ipsen Pharma Sas | CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS |
| EP2979703B1 (en) * | 2007-11-05 | 2018-07-18 | Ipsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
| EP2297178B1 (en) | 2008-05-27 | 2014-07-30 | Genzyme Corporation | Peptide analogs of alpha-melanocyte stimulating hormone |
| EP2300036B1 (en) | 2008-06-09 | 2017-04-05 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| WO2010144341A2 (en) | 2009-06-08 | 2010-12-16 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
| BRPI1009644B1 (pt) | 2009-06-08 | 2022-02-08 | Palatin Technologies, Inc | Peptídeo cíclico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso da composição farmacêutica |
| MX2012001513A (es) * | 2009-08-05 | 2012-05-22 | Ipsen Pharma Sas | Uso de melanocortinas para tratar la dislipidemia. |
| ES2624451T3 (es) * | 2009-08-31 | 2017-07-14 | Tensive Controls, Inc. | Ligandos de melanocortina estabilizados |
| JP5486690B2 (ja) * | 2009-11-16 | 2014-05-07 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | メラノコルチン受容体リガンドの医薬組成物 |
| WO2011060355A1 (en) * | 2009-11-16 | 2011-05-19 | Ipsen Pharma S.A.S | Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2 |
| EP2504351A4 (en) | 2009-11-23 | 2013-10-30 | Palatin Technologies Inc | MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE |
| AU2010321738B2 (en) | 2009-11-23 | 2016-07-14 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific cyclic peptides |
| KR102038677B1 (ko) * | 2011-06-14 | 2019-10-30 | 입센 파마 에스.에이.에스 | 활성 성분으로 멜라노코르틴 수용체 리간드를 함유하는 지속-방출형 조성물 |
| SMT202100734T1 (it) | 2011-12-29 | 2022-03-21 | Rhythm Pharmaceuticals Inc | Metodo di trattamento di disturbi associati al recettore di melanocortina 4 in portatori eterozigoti |
| EP2705835A1 (en) | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
| WO2014060606A1 (en) * | 2012-10-19 | 2014-04-24 | Txp Pharma Gmbh | Alpha- and gamma-msh analogues |
| WO2014153221A2 (en) | 2013-03-14 | 2014-09-25 | Questcor Pharmaceuticals, Inc. | Acth for treatment of acute respiratory distress syndrome |
| JP6538025B2 (ja) | 2013-03-15 | 2019-07-03 | リズム・ファーマシューティカルズ・インコーポレイテッド | 医薬組成物 |
| JP6622690B2 (ja) | 2013-03-15 | 2019-12-18 | リズム・ファーマシューティカルズ・インコーポレイテッド | ペプチド組成物 |
| HUE052977T2 (hu) | 2014-04-22 | 2021-06-28 | Txp Pharma Gmbh | Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok) |
| MX2018003983A (es) | 2015-09-30 | 2018-11-09 | Rhythm Pharmaceuticals Inc | Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4. |
| WO2018074999A1 (en) * | 2016-10-17 | 2018-04-26 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Novel modulators of melanocortin receptors for the treatment of depression and anxiety |
| US10653743B2 (en) * | 2015-10-15 | 2020-05-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N |
| US11542302B2 (en) | 2015-10-15 | 2023-01-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modulators of melanocortin receptors for the treatment of depression and anxiety |
| US20200223889A1 (en) * | 2017-03-15 | 2020-07-16 | Novo Nordisk A/S | Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor |
| CA3096055A1 (en) | 2018-04-06 | 2019-10-10 | Rhythm Pharmaceuticals, Inc. | Compositions for treating kidney disease |
| WO2019219714A1 (en) * | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
| CA3100868A1 (en) * | 2018-05-23 | 2019-11-28 | Provincial Health Services Authority | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy |
| US11396535B2 (en) | 2019-03-01 | 2022-07-26 | Provincial Health Services Authority | Cyclic peptide analogs of melanocortin and amanitin and methods of making such |
| JP2023542985A (ja) * | 2020-09-24 | 2023-10-12 | リズム ファーマシューティカルズ， インコーポレイテッド | メラノコルチン－４受容体経路関連障害の治療方法 |
| CA3213099A1 (en) * | 2021-03-24 | 2022-09-29 | Robert A. Love | Peptides and methods for reducing skin pigmentation |
| JP2024522348A (ja) * | 2021-05-27 | 2024-06-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ｍｃ３ｒアゴニストペプチド |
| US20260103529A1 (en) | 2022-10-18 | 2026-04-16 | Confo Therapeutics N.V. | Amino Acid Sequences Directed Against the Melanocortin 4 Receptor and Polypeptides Comprising the Same for the Treatment of MC4R-Related Diseases and Disorders |
| WO2025123056A1 (en) * | 2023-12-07 | 2025-06-12 | Endevica Bio, Inc. | Non-naturally occurring melanocortin analogs and associated methods |
| WO2025245288A1 (en) * | 2024-05-22 | 2025-11-27 | Endevica Bio, Inc. | Non-naturally occurring melanocortin analogs and uses thereof |
| CN120699097B (zh) * | 2024-09-03 | 2026-06-12 | 万邦德制药集团有限公司 | 一种二硫环肽化合物及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US613874A (en) | 1898-11-08 | George e | ||
| US1613874A (en) | 1922-03-29 | 1927-01-11 | Miner Inc W H | Friction draft gear |
| US5652214A (en) | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| SE9700620D0 (sv) | 1997-02-21 | 1997-02-21 | Wapharm Ab | Cykliska peptider med selektivitet för MSH-receptor subtyper |
| AU7464998A (en) | 1997-10-27 | 1999-05-17 | Trega Biosciences, Inc. | Melanocortin receptor ligands and methods of using same |
| US6127381A (en) * | 1998-04-28 | 2000-10-03 | Basu; Amaresh | Isoquinoline compound melanocortin receptor ligands and methods of using same |
| AU758179B2 (en) * | 1998-07-27 | 2003-03-20 | Iowa State University Research Foundation Inc. | Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals |
| WO2000010507A2 (en) | 1998-08-21 | 2000-03-02 | The Children's Medical Center Corporation | Use of melanin for inhibition of angiogenesis and macular degeneration |
| US6603058B1 (en) | 1998-12-09 | 2003-08-05 | Oklahoma Medical Research Foundation | Non-human animal model for obesity and uses thereof |
| US6716810B1 (en) | 1998-12-09 | 2004-04-06 | Eleanor Roosevelt Institute | Composition and method for regulation of body weight and associated conditions |
| HK1044954B (en) * | 1999-03-29 | 2008-11-21 | The Procter & Gamble Company | Melanocortin receptor ligands |
| US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
| US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
| US6639123B1 (en) | 1999-11-12 | 2003-10-28 | Merck & Co., Inc. | Melanocortin-3 receptor deficient cells, non-human trangenic animals and methods of selecting compounds which regulate body weight |
| US6600015B2 (en) | 2000-04-04 | 2003-07-29 | Hoffmann-La Roche Inc. | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
| BR0111567A (pt) * | 2000-06-28 | 2003-05-06 | Pfizer Prod Inc | Ligandos do receptor de melanocortina |
| US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
| US6689938B2 (en) | 2000-09-13 | 2004-02-10 | Oklajoma Medical Research Foundation | Method for treatment of insulin resistance in obesity and diabetes |
| US20030113263A1 (en) | 2001-02-13 | 2003-06-19 | Oregon Health And Sciences University, A Non-Profit Organization | Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia |
| EP1363898A4 (en) | 2001-03-02 | 2004-12-08 | Bristol Myers Squibb Co | COMPOUNDS SUITABLE AS MODULATORS OF MELANOCORTIN RECEPTORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US6770645B2 (en) * | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
| AU2002322466B2 (en) * | 2001-07-11 | 2007-08-30 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptides |
| US7034004B2 (en) | 2002-05-07 | 2006-04-25 | University Of Florida | Peptides and methods for the control of obesity |
| US20040128136A1 (en) * | 2002-09-20 | 2004-07-01 | Irani Pourang Polad | Internet voice browser |
| WO2005000338A1 (en) * | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Uses of melanocortin-3 receptor (mc3r) agonist peptides |
| EA200600055A1 (ru) * | 2003-06-19 | 2006-08-25 | Эли Лилли Энд Компани | Агонисты рецептора меланокортина 4 (мк4 ) и их применение |
| US7084111B2 (en) | 2003-06-23 | 2006-08-01 | University Of Florida Research Foundation, Inc. | Melanocortin receptor templates, peptides, and use thereof |
| EP1658273B1 (en) | 2003-08-20 | 2007-01-03 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
| ES2286679T3 (es) | 2003-08-20 | 2007-12-01 | Eli Lilly And Company | Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4). |
| US20050192286A1 (en) * | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| DE10355559A1 (de) | 2003-11-21 | 2005-06-23 | Orthogen Ag | Transskin |
| WO2005060985A1 (en) | 2003-12-10 | 2005-07-07 | Merck & Co., Inc. | Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists |
| EP1732586A1 (en) | 2004-03-29 | 2006-12-20 | Eli Lilly And Company | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion |
| NZ554427A (en) | 2004-10-08 | 2010-09-30 | Clinuvel Pharmaceuticals Ltd | Compositions and methods for inducing melanogenesis in a subject utilising afamelanotide |
| WO2006073771A2 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
| WO2006073772A1 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
| ES2663916T3 (es) * | 2005-07-08 | 2018-04-17 | Ipsen Pharma | Ligandos de los receptores de la melanocortina |
| ES2407107T3 (es) | 2005-08-26 | 2013-06-11 | Abbvie Inc. | Análogos de alfa-MSH terapéuticamente activos |
-
2006
- 2006-07-10 ES ES12188784.8T patent/ES2663916T3/es not_active Expired - Lifetime
- 2006-07-10 CA CA2793119A patent/CA2793119C/en not_active Expired - Lifetime
- 2006-07-10 CA CA3044795A patent/CA3044795A1/en not_active Abandoned
- 2006-07-10 SI SI200632406T patent/SI3354273T1/sl unknown
- 2006-07-10 SG SG201004921-1A patent/SG163585A1/en unknown
- 2006-07-10 CN CN202411273113.9A patent/CN119119190A/zh active Pending
- 2006-07-10 NZ NZ565217A patent/NZ565217A/en unknown
- 2006-07-10 ES ES10170694T patent/ES2386862T3/es not_active Expired - Lifetime
- 2006-07-10 CN CN201310495024.4A patent/CN103755786B/zh not_active Expired - Lifetime
- 2006-07-10 WO PCT/US2006/026586 patent/WO2007008704A2/en not_active Ceased
- 2006-07-10 KR KR1020097022845A patent/KR101232201B1/ko not_active Expired - Lifetime
- 2006-07-10 PT PT101825669T patent/PT2286825T/pt unknown
- 2006-07-10 CN CN201610168908.2A patent/CN105837661B/zh not_active Expired - Lifetime
- 2006-07-10 ES ES17202836T patent/ES2877349T3/es not_active Expired - Lifetime
- 2006-07-10 HU HUE10182566A patent/HUE031731T2/en unknown
- 2006-07-10 CA CA3228910A patent/CA3228910A1/en active Pending
- 2006-07-10 NZ NZ580806A patent/NZ580806A/en not_active Application Discontinuation
- 2006-07-10 US US11/988,533 patent/US8039435B2/en active Active
- 2006-07-10 RU RU2009131092/04A patent/RU2439079C2/ru active
- 2006-07-10 KR KR1020087002955A patent/KR100997177B1/ko not_active Expired - Lifetime
- 2006-07-10 DK DK17202836.7T patent/DK3354273T3/da active
- 2006-07-10 EP EP12188784.8A patent/EP2548568B1/en not_active Expired - Lifetime
- 2006-07-10 AU AU2006269261A patent/AU2006269261B2/en not_active Expired
- 2006-07-10 DK DK10170694.3T patent/DK2236151T3/da active
- 2006-07-10 DK DK10182566.9T patent/DK2286825T3/en active
- 2006-07-10 CN CN200910174061A patent/CN101676298A/zh active Pending
- 2006-07-10 RU RU2008104803/04A patent/RU2380372C2/ru active
- 2006-07-10 EP EP10182566.9A patent/EP2286825B1/en not_active Expired - Lifetime
- 2006-07-10 JP JP2008520417A patent/JP4734411B2/ja not_active Expired - Lifetime
- 2006-07-10 PL PL17202836T patent/PL3354273T3/pl unknown
- 2006-07-10 PL PL12188784T patent/PL2548568T3/pl unknown
- 2006-07-10 PT PT10170694T patent/PT2236151E/pt unknown
- 2006-07-10 CA CA2614615A patent/CA2614615C/en not_active Expired - Lifetime
- 2006-07-10 PL PL10170694T patent/PL2236151T3/pl unknown
- 2006-07-10 EP EP10170694A patent/EP2236151B1/en not_active Expired - Lifetime
- 2006-07-10 HU HUE17202836A patent/HUE055154T2/hu unknown
- 2006-07-10 EP EP06786665A patent/EP1915167A4/en not_active Withdrawn
- 2006-07-10 PL PL10182566T patent/PL2286825T3/pl unknown
- 2006-07-10 PT PT121887848T patent/PT2548568T/pt unknown
- 2006-07-10 EP EP17202836.7A patent/EP3354273B1/en not_active Expired - Lifetime
- 2006-07-10 DK DK12188784.8T patent/DK2548568T3/en active
- 2006-07-10 CN CN2006800324235A patent/CN101257916B/zh not_active Expired - Lifetime
- 2006-07-10 ES ES10182566.9T patent/ES2604328T3/es not_active Expired - Lifetime
- 2006-07-10 EP EP21163411.8A patent/EP3925614A3/en active Pending
- 2006-07-10 PT PT172028367T patent/PT3354273T/pt unknown
- 2006-07-10 HU HUE12188784A patent/HUE037147T2/hu unknown
-
2008
- 2008-01-02 IL IL188545A patent/IL188545A/en active IP Right Grant
-
2009
- 2009-10-25 IL IL201732A patent/IL201732A/en active IP Right Grant
- 2009-10-28 AU AU2009230799A patent/AU2009230799B2/en not_active Expired
- 2009-11-19 JP JP2009263603A patent/JP5889513B2/ja not_active Expired - Lifetime
-
2011
- 2011-03-29 US US13/074,565 patent/US9458195B2/en active Active
-
2013
- 2013-08-08 JP JP2013165312A patent/JP2013253090A/ja active Pending
-
2015
- 2015-07-14 JP JP2015140154A patent/JP5965520B2/ja not_active Expired - Lifetime
-
2016
- 2016-06-22 IL IL246392A patent/IL246392A/en active IP Right Grant
- 2016-09-07 US US15/257,970 patent/US20160368962A1/en not_active Abandoned
-
2017
- 2017-05-05 US US15/587,426 patent/US9850280B2/en not_active Expired - Lifetime
- 2017-12-04 US US15/830,038 patent/US20180105557A1/en not_active Abandoned
-
2018
- 2018-07-09 US US16/029,837 patent/US20180305406A1/en not_active Abandoned
-
2019
- 2019-12-04 US US16/702,661 patent/US20200095281A1/en not_active Abandoned
-
2021
- 2021-12-06 NL NL301150C patent/NL301150I2/nl unknown
- 2021-12-07 BE BE2021C557C patent/BE2021C557I2/nl unknown
- 2021-12-14 FR FR21C1060C patent/FR21C1060I2/fr active Active
- 2021-12-15 HU HUS2100054C patent/HUS2100054I1/hu unknown
-
2022
- 2022-01-10 US US17/572,115 patent/US20220127305A1/en not_active Abandoned
-
2025
- 2025-04-28 US US19/191,698 patent/US20260085092A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2100054I1 (hu) | Melanokortin receptor ligandumok | |
| NL300997I2 (nl) | Fremanezumab | |
| ATE408603T1 (de) | Pyrazolylcarboxanilide | |
| CR9974A (es) | Gavión | |
| DE602006002078D1 (de) | Gurtbandaufwickelvorrichtung | |
| DE602006018635D1 (de) | Triarylcarbonsäurederivat | |
| ATE549324T1 (de) | Tetrahydrobenzoxazine | |
| DE112005003670A5 (de) | Eventanordnung | |
| FI20055078L (fi) | Yhteistoiminta | |
| DE102005052834B8 (de) | Punktschweißklebverbindung | |
| ATE485368T1 (de) | Hiv - impfung | |
| AT501523A3 (de) | Estrich | |
| ITRM20050271A1 (it) | Stuoia. | |
| DE102006033170A8 (de) | Einfassnähmaschine | |
| FI7102U1 (fi) | Istuin | |
| DE502006002564D1 (de) | Ndungen | |
| AT501968A3 (de) | Mitführhilfe | |
| EP1915490A4 (en) | DUCH TOUR ARRANGEMENT | |
| UA11842S (uk) | Кронштейн | |
| FI20055601A7 (fi) | Kannatin | |
| SE0502247L (sv) | Referenslinje | |
| FI20040097A0 (fi) | Monikiinnitin | |
| DE502006007306D1 (de) | Halterungsanordnung | |
| ES1061306Y (es) | Mosquitera mejorada | |
| DE602006012577D1 (de) | Konstruktionselement |